ArticleCell reports2021
Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection.
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 38 citations in OpenAlex.
- Generation and Characterization of the Human Anti-HTNV Antibody KJJ4.International journal of molecular sciences · 2026Article
- Respiratory mucosal vaccines for emerging viruses: promise and challenges.Journal of virology · 2026Review
- Vaccines and therapeutics for Andes hantavirus.Npj viruses · 2026Article
- Article
- Cross-binding antibodies capable of neutralising diverse hantaviruses are produced in response to Puumala virus infection.EBioMedicine · 2026Article
- A review of post-exposure strategies for high-consequence viral pathogens in the laboratory.Clinical microbiology reviews · 2025Review
- Hantavirus GnACS infectious diseases · 2025Article
- Article
- Article
- A pan-orthohantavirus human lung xenograft mouse model and its utility for preclinical studies.PLoS pathogens · 2025Article
- Puumala orthohantavirus: prevalence, biology, disease, animal models and recent advances in therapeutics development and structural biology.Frontiers in immunology · 2025Review
- Molecular insight into the neutralization mechanism of human-origin monoclonal antibody AH100 against Hantaan virus.Journal of virology · 2024Article
- Crimean-Congo hemorrhagic fever survivors elicit protective non-neutralizing antibodies that target 11 overlapping regions on glycoprotein GP38.Cell reports · 2024Article
- The Adaptive Immune Response againstViruses · 2024Review
- Crimean-Congo Hemorrhagic Fever Survivors Elicit Protective Non-Neutralizing Antibodies that Target 11 Overlapping Regions on Viral Glycoprotein GP38.bioRxiv : the preprint server for biology · 2024Article
- Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.Cellular and molecular life sciences : CMLS · 2024Review
- Review
- Multifunctional human monoclonal antibody combination mediates protection against Rift Valley fever virus at low doses.Nature communications · 2023Article
- Mechanistic basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody.Nature microbiology · 2023Article
- Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody.Science translational medicine · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
New World hantaviruses (NWHs) are endemic in North and South America and cause hantavirus cardiopulmonary syndrome (HCPS), with a case fatality rate of up to 40%. Knowledge of the natural humoral immune response to NWH infection is limited. Here, we describe human monoclonal antibodies (mAbs) isolated from individuals previously infected with Sin Nombre virus (SNV) or Andes virus (ANDV). Most SNV-reactive antibodies show broad recognition and cross-neutralization of both New and Old World hantaviruses, while many ANDV-reactive antibodies show activity for ANDV only. mAbs ANDV-44 and SNV-53 compete for binding to a distinct site on the ANDV surface glycoprotein and show potently neutralizing activity to New and Old World hantaviruses. Four mAbs show therapeutic efficacy at clinically relevant doses in hamsters. These studies reveal a convergent and potently neutralizing human antibody response to NWHs and suggest therapeutic potential for human mAbs against HCPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.